Your browser doesn't support javascript.
loading
Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
Bayliss, Julianne; Yuen, Lilly; Rosenberg, Gillian; Wong, Darren; Littlejohn, Margaret; Jackson, Kathleen; Gaggar, Anuj; Kitrinos, Kathryn M; Subramanian, G Mani; Marcellin, Patrick; Buti, Maria; Janssen, Harry L A; Gane, Ed; Sozzi, Vitina; Colledge, Danni; Hammond, Rachel; Edwards, Rosalind; Locarnini, Stephen; Thompson, Alexander; Revill, Peter A.
  • Bayliss J; Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Yuen L; Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Rosenberg G; Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Wong D; Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Littlejohn M; Department of Gastroenterology, St. Vincent's Hospital, Melbourne, Victoria, Australia.
  • Jackson K; Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Gaggar A; Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Kitrinos KM; Gilead Sciences, Foster City, California, USA.
  • Subramanian GM; Gilead Sciences, Foster City, California, USA.
  • Marcellin P; Gilead Sciences, Foster City, California, USA.
  • Buti M; Hôpital Beaujon, University of Paris, Clichy, France.
  • Janssen HLA; Liver Unit, Valle d'Hebron (Ciberehd) University Hospital, Barcelona, Spain.
  • Gane E; Toronto Center for Liver Diseases, Toronto Western and General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Sozzi V; New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand.
  • Colledge D; Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Hammond R; Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Edwards R; Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Locarnini S; Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Thompson A; Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Revill PA; Department of Gastroenterology, St. Vincent's Hospital, Melbourne, Victoria, Australia.
Gut ; 66(11): 2013-2023, 2017 11.
Article en En | MEDLINE | ID: mdl-27534671
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antivirales / Virus de la Hepatitis B / Regiones Promotoras Genéticas / Hepatitis B Crónica / Tenofovir / Seroconversión Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antivirales / Virus de la Hepatitis B / Regiones Promotoras Genéticas / Hepatitis B Crónica / Tenofovir / Seroconversión Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2017 Tipo del documento: Article